About: Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana
Creator	Nii-Trebi, Nicholas Abana, Yen Asamoah-Akuoko, Lucy Mawuli, Gifty Obeng, Billal Sagoe, Coleman William, Kwamena Yayra Bonney, Evelyn Zaab, Christopher
Source	Medline; PMC
abstract	BACKGROUND: Detection of HIV-1 transmitted drug resistance (TDR) and subtype diversity (SD) are public health strategies to assess current HIV-1 regimen and ensure effective therapeutic outcomes of antiretroviral therapy (ART) among HIV-1 patients. Globally, limited data exist on TDR and SD among blood donors. In this study, drug resistance mutations (DRMs) and SD amongst HIV-1 sero-positive blood donors in Accra, Ghana were characterized. METHODS: Purposive sampling method was used to collect 81 HIV sero-positive blood samples from the Southern Area Blood Center and confirmed by INNO-LIA as HIV-1 and/or HIV-2. Viral RNA was only extracted from plasma samples confirmed as HIV-1 positive. Complementary DNA (cDNA) was synthesized using the RNA as a template and subsequently amplified by nested PCR with specific primers. The expected products were verified, purified and sequenced. Neighbour-joining tree with the Kimura’s 2-parameter distances was generated with the RT sequences using Molecular Evolutionary Genetic Analysis version 6.0 (MEGA 6.0). RESULTS: Out of the 81 plasma samples, 60 (74%) were confirmed as HIV-1 sero-positive by INNO-LIA HIVI/II Score kit with no HIV-2 and dual HIV-1/2 infections. The remaining samples, 21 (26%) were confirmed as HIV sero-negative. Of the 60 confirmed positive samples, (32) 53% and (28) 47% were successfully amplified in the RT and PR genes respectively. Nucleotide sequencing of amplified samples revealed the presence of major drug resistance mutations in two (2) samples; E138A in one sample and another with K65R. HIV-1 Subtypes including subtypes A, B, CRF02_AG and CRF09_cpx were found. CONCLUSION: This study found major drug resistance mutations, E138A and K65R in the RT gene that confer high level resistance to most NNRTIs and NRTI respectively. CRF02_AG was most predominant, the recorded percentage of subtype B and the evolutionary relationship inferred by phylogenetic analysis may suggest possible subtype importation. However, a more prospective and detailed analysis is needed to establish this phenomenon. The data obtained would inform the selection of drugs for ART initiation to maximize therapeutic options in drug-naïve HIV-1 patients in Ghana.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1186/s12985-020-01386-y
bibo:pmid	32709248
has license	cc-by
sha1sum (hex)	944c08b3816e8cf6553c42f85a5fc2bf2d67e1ed
schema:url	https://doi.org/10.1186/s12985-020-01386-y
resource representing a document's title	Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana
has PubMed Central identifier	PMC7378406
has PubMed identifier	32709248
schema:publication	Virol J
resource representing a document's body	covid:944c08b3816e8cf6553c42f85a5fc2bf2d67e1ed#body_text
is schema:about of	named entity 'exist' named entity 'patients' named entity 'subtype' named entity 'Accra' named entity 'Accra' named entity 'effective' named entity 'HIV infection' named entity 'HIV' named entity 'HIV-1' named entity 'HIV' named entity 'primers' named entity 'genotypic' named entity 'peripheral blood mononuclear cells' named entity 'Europe' named entity 'QIAGEN' named entity 'drug resistant' named entity 'blood donors' named entity 'Mannheim' named entity 'RNA' named entity 'HIV status' named entity 'PCR' named entity 'Hilden' named entity 'viruses' named entity 'cDNA' named entity 'Ghana' named entity 'menstruation' named entity 'Viral' named entity 'Genetic Analysis' named entity 'Drug resistance' named entity 'QIAGEN' named entity 'virologic failure' named entity 'zidovudine' named entity 'Phylogenetic analysis' named entity '19, 20' named entity 'EFV' named entity 'SABC' named entity 'physically active' named entity 'Ghana' named entity 'abacavir' named entity 'Ghanaian' named entity 'Antrim' named entity 'primer' named entity 'nuclease' named entity 'RNA' named entity 'Ghana' named entity 'University of Ghana' named entity 'contig' named entity 'Agencourt Bioscience' named entity 'HIV-1' named entity 'Ethics' named entity 'blood bank' named entity 'primers' named entity 'drug resistance' named entity 'Ghana' named entity 'HIV pandemic' named entity 'drug resistance' named entity 'Germany' named entity 'Ghana' named entity 'complementary DNA' named entity 'random hexamer' named entity 'protease inhibitors' named entity 'rilpivirine' named entity 'Ghana' named entity 'HIV-1' named entity 'current' named entity 'HIV-1' named entity 'blood donors' named entity 'blood donors' named entity 'Ghana' named entity 'drug resistance' named entity 'public health' named entity 'HIV-1' named entity 'HIV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software